CITIUS ONCOLOGY, INC. (CTOR)
2025-06-30 | 2025-03-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenues | - | - | - | |
| Research and development | 938,277 | 3,139,413 | 1,264,508 | |
| General and administrative | 1,881,447 | 2,243,327 | 3,321,979 | |
| Stock-based compensation general and administrative | 2,125,237 | - | 1,808,478 | |
| Stock-based compensation general and administrative | - | 2,088,572 | - | |
| Total operating expenses | 4,944,961 | 7,471,312 | 6,394,965 | |
| Revenues | - | - | - | |
| Operating loss | -4,944,961 | - | - | |
| Interest expense | 160,755 | - | - | |
| Loss before income taxes | -5,105,716 | -7,471,312 | -6,394,965 | |
| Income tax expense | 264,240 | 264,240 | 264,240 | |
| Net loss | -5,369,956 | -7,735,552 | -6,659,205 | |
| Net loss per share diluted (in dollars per share) | -0.08 | -0.11 | -0.09 | |
| Net loss per share - basic (in dollars per share) | -0.08 | -0.11 | -0.09 | |
| Weighted average common shares outstanding basic (in shares) | 71,552,402 | 71,552,402 | 71,552,402 | |
| Weighted average common shares outstanding diluted (in shares) (in shares) | 71,552,402 | 71,552,402 | 71,552,402 | |